Unfortunately, not all is ever that easy. If we were to follow Mark's
rules, glycoproteins would end up losing their asparagines (and others
residues depending on the type of glycosylation) to numerous
underdefined new residue types. And consider the confusion caused by the
different versions o
Dear Marc (and BB),
I guess as usual, in real life the obvious is less obvious as it seems to be.
I, and I guess many of my colleagues trying to find new drugs, have quite a few
protein-inhibitor complexes where the inhibitor formed a covalent link with
e.g. the active site serine. In these cas
